Heavy metal lead exposure, osteoporotic-like phenotype in an animal model, and depression of Wnt signaling

Environmental Health Perspectives

Volumn 121, Issue 1, 2013, Pages 97-104

  Beier, Eric E ^a   Maher, Jason R ^b   Sheu, Tzong Jen ^a   Cory Slechta, Deborah A ^a   Berger, Andrew J ^b   Zuscik, Michael J ^a   Edward Puzas, J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Bone mineral density; Lead; Mesenchymal stem cells; Rat; Wnt signaling

Indexed keywords

BETA CATENIN; FAT DROPLET; LEAD; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SCLEROSTIN; TRANSCRIPTION FACTOR RUNX2;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BONE DENSITOMETRY; BONE MASS; CONTROLLED STUDY; DEPRESSION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENVIRONMENTAL EXPOSURE; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; RADIOGRAPHY; RAMAN SPECTROMETRY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SPECTROSCOPY; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

ANIMALIA; RATTUS; RODENTIA;

EID: 84872060161     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1205374     Document Type: Article

References (40)

1. Bagchi D, Preuss HG. 2005. Effects of acute and chronic oval exposure of lead on blood pressure and bone mineral density in rats. J Inorg Biochem 99(5):1155-1164.
2. Barth RW, Williams JL, Kaplan FS. 1992. Osteon morphometry in females with femoral neck fractures. Clin Orthop Relat Res 283:178-186.
3. Campbell JR, Auinger P. 2007. The association between blood lead levels and osteoporosis among adults-results from the Third National Health and Nutrition Examination Survey (NHANES III). Environ Health Perspect 115:1018-1022.
4. Carmouche JJ, Puzas JE, Zhang X, Tiyapatanaputi P, Cory-Slechta DA, Gelein R, et al. 2005. Lead exposure inhibits fracture healing and is associated with increased chondrogenesis, delay in cartilage mineralization, and a decrease in osteoprogenitor frequency. Environ Health Perspect 113:749-755.
5. Centers for Disease Control and Prevention. 1991. Preventing Lead Poisoning in Young Children. Atlanta, GA:Centers for Disease Control and Prevention. Available: http://www.cdc.gov/nceh/lead/publications/prevleadpoisoning.pdf [accessed 27 November 2012].
6. Chen JR, Lazarenko OP, Shankar K, Blackburn ML, Badger TM, Ronis MJ. 2010. A role for ethanol-induced oxidative stress in controlling lineage commitment of mesenchymal stromal cells through inhibition of Wnt/β-catenin signaling. J Bone Miner Res 25(5):1117-1127.
7. Cho YC, Jefcoate CR. 2004. PPARγ1 synthesis and adipogenesis in C3H10T1/2 cells depends on S-phase progression, but does not require mitotic clonal expansion. J Cell Biochem 91(2):336-353.
8. Cory-Slechta DA, Stern S, Weston D, Allen JL, Lui S. 2010. Enhanced learning deficits in female rats following lifetime Pb exposure combined with prenatal stress. Toxicol Sci 117(2):427-438.
9. 2+ on the structure and hydroxyapatite binding properties of osteocalcin. Biochim Biophys Acta 1535:153-163.
10. Escribano A, Revilla M, Hernandez ER, Seco C, Gonzalez-Riola J, et al. 1997. Effect of lead on bone development and bone mass: a morphometric, densitometric, and histomorphometric study in growing rats. Calcif Tissue Int 60(2):200-203.
11. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, et al. 2009. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114(2):371-379.
12. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME. 2006. Playing with bone and fat. J Cell Biochem 98(2):251-266.
13. Goyer RA. 1993. Lead toxicity: current concerns. Environ Health Perspect 100:177-187.
14. Gruber HE, Gonick HC, Khalil-Manesh F, Sanchez TV, Motsinger S, Meyer M, et al. 1997. Osteopenia induced by long-term, low- and high-level exposure of the adult rat to lead. Miner Electrolyte Metab 23(2):65-73.
15. Guo R, Yamashita M, Zhang Q, Zhou Q, Chen D, Reynolds DG, et al. 2008. Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J Biol Chem 283(34):23084-23092.
16. Johnson ML, Gong G, Kimberling W, Recker SM, Kimmel DB, Recker RB. 1997. Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am J Hum Genet 60(6):1326-1332.
17. Johnson ML, Harnish K, Nusse R, Van Hul W. 2004. LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res 19(11):1749-1757.
18. Khalil N, Cauley JA, Wilson JW, Talbott EO, Morrow L, Hochber MC, et al. 2008. Relationship of blood lead levels to incident nonspine fractures and falls in older women: the study of osteoporotic fractures. J Bone Miner Res 23(9):1217-1225.
19. Klein RF, Wiren KM. 1993. Regulation of osteoblastic gene expression by lead. Endocrinology 132:2531-2537.
20. Li FQ, Singh AM, Mofunanya A, Love D, Terada N, Moon RT, et al. 2007. Chibby promotes adipocyte differentiation through inhibition of β-catenin signaling. Mol Cell Biol 27(12):4347-4354.
21. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, et al. 2008. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23(6):860-869.
22. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24(4):578-588.
23. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. 2005. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280(20):19883-19887.
24. Mahaffey KR, Annest JL, Roberts J, Murphy RS. 1982. National estimates of blood lead levels: United States, 1976-1980: association with selected demographic and socioeconomic factors. N Engl J Med 307:573-579.
25. Maher JR, Takahata M, Awad HA, Berger AJ. 2011. Raman spectroscopy detects deterioration in biomechanical properties of bone in a glucocorticoid-treated mouse model of rheumatoid arthritis. J Biomed Opt 16(8):087012.
26. Monir AU, Gundberg CM, Yagerman SE, van der Meulen MCH, Budell W, Bosky AL, et al. 2010. The effect of lead on bone mineral properties from female adult C57/BL6 mice. Bone 47(5):888-894.
27. Nash D, Magder LS, Sherwin R, Rubin FJ, Silbergeld EK. 2004. Bone density-related predictors of blood lead level among peri- and postmenopausal women in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 160(9):901-911.
28. Nuttall ME, Gimble JM. 2004. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 4(3):290-294.
29. Padhi D, Jang G, Stouch B, Fang L, Posvar E. 2011. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26(1):19-26.
30. Parsons PJ. 1993. A rapid Zeeman graphite furnace atomic absorption spectrometric method for the determination of lead in blood. Spectrochim Acta 48B:925-939.
31. Puzas JE, Campbell JR, O'Keefe RJ, Rosier RN. 2004. Lead toxicity in the skeleton and its role in osteoporosis. In: Nutrition and Bone Heath (Holick MF, Dawson-Hughes B, eds). Totowa, NJ:Humana Press, 363-376.
32. Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, Cullen DM, Zhao W, Li C, et al. 2006. Wnt/β-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem 281(42):31720-31728.
33. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, et al. 2000. Inhibition of adipogenesis by Wnt signaling. Science 289(5481):950-953.
34. Ryan EP, Holz JD, Mulcahey M, Sheu TJ, Gasiewicz, TA, Puzas JE. 2007. Environmental toxicants may modulate osteoblast differentiation by a mechanism involving the aryl hydrocarbon receptor. J Bone Miner Res 22(10):1571-1580.
35. Sauk JJ, Smith T, Silbergeld EK, Fowler BA, Somerman MJ. 1992. Lead inhibits secretion of osteonectin/SPARC without significantly altering collagen or Hsp47 production in osteoblast-like ROS 17/2.8. Toxicol Appl Pharmacol 116(2):240-247.
36. Shahnazari M, Yao W, Corr M, Lane NE. 2008. Targeting the Wnt signaling pathway to augment bone formation. Curr Osteoporos Rep 6(4):142-148.
37. Syed FA, Oursler MJ, Hefferanm TE, Peterson JM, Riggs BL, Khosla S. 2008. Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Osteoporos Int 19(9):1323-1330.
38. van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW. 2005. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16(3):319-327.
39. Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ. 2002. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 55(9):693-698.
40. Wachter NJ, Krischak GD, Mentzel M, Sarkar MR, Ebinger T, Kinzl L, et al. 2002. Correlation of bone mineral density with strength and microstructural parameters of cortical bone in vitro. Bone 31(1):90-95.